ProCE Banner Activity

Adapting to the Changing Treatment Landscape in Early Breast Cancer

Clinical Thought
In this commentary, I share my thoughts on the impact of recent data on treatment planning in early breast cancer, including how to incorporate PARP inhibition, CDK4/6 inhibition, and immunotherapy, along with the dilemmas and challenges surrounding their use.

Released: February 22, 2022

Expiration: February 21, 2023

No longer available for credit.

Share

Faculty

Denise A. Yardley

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Program Director Disclosure

Program Director

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Denise A. Yardley, MD, has disclosed that she has received consulting fees from from Athenex, bioTheranostics, G1 Therapeutics, Immunomedics, Lilly, Merck, Novartis, Pfizer, and Sanofi-Aventis and funds for research support paid to her institution from AbbVie, Amgen, Biothera, Clovis Pharma, Lilly, Roche/Genentech, Incyte, Innocrin, MacroGenics, MedImmune, Medivation, Merck, Merrimack, Nektar, Novartis, NSABP, Pfizer, Polyphor, and Tesaro.